Vadeboncoeur, Alain
Marcil, Marie-Joelle
Cyr, Samuel
Gupta, Mona
Cournoyer, Alexis
Minichiello, Anthony
Larose, Dominic
Sirois-Leclerc, Julie
Tardif, Jean-Claude
Morin, Josée
Masson, Violaine
Cossette, Mariève
Brouillette, Judith http://orcid.org/0000-0002-2602-7987
Funding for this research was provided by:
Fondation Institut de Cardiologie de Montréal
Article History
Received: 9 December 2021
Accepted: 24 March 2022
First Online: 3 May 2022
Declarations
:
: Dr. Tardif reports grants from Amarin, grants and personal fees from Astra Zeneca, grants, personal fees and others from Dalcor Pharmaceuticals, grants from Esperion, grants from Ionis, grants from Pfizer, grants from Ceapro, grants from Novartis, grants from RegenXBio, honoraria from Pendopharm, personal fees from HLS Therapeutics, and stock ownership of DalCor Pharmaceuticals (minor equity interest) outside the submitted work; In addition, Dr. Tardif has a patent Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent pending, and a patent Methods for using low dose colchicine after myocardial infarction with royalties paid to Invention assigned to the Montréal Heart Institute. Dr. Vadeboncoeur participates in a study granted by Cipher. V. Masson reports consulting fees from Otsuka-Lundbeck and Jamp Pharma.